Imvax, Inc.
Biotechnology ResearchPennsylvania, United States11-50 Employees
Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing personalized, whole tumor-derived immunotherapies. Its lead program aims to treat glioblastoma multiforme (GBM), a highly aggressive brain cancer, with additional efforts in other solid tumors. The company emphasizes a holistic approach that captures the complete antigenic signature of a patient’s tumor and translates it into an immune system training program designed to stimulate both innate and adaptive responses for potentially longer-lasting anti-tumor effects. Operating within the biotechnology research sector, Imvax positions itself at the intersection of personalized cancer immunotherapy and complex solid-tumor treatment. Its activities center on advancing therapies that leverage a patient-specific tumor profile to inform treatment, with ongoing work across GBM and other solid tumors. The organization is headquartered in Philadelphia and operates with a development trajectory typical of clinical-stage biotechs pursuing multi-program goals aligned with precision oncology.
1-888-653-2347 
support@leadiq.com 
